Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.

Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.

Abstract: Compounds having the general formula (I): are provided which have enhanced inhibitory potency and are thus useful in methods of prophylaxis or treatment of a viral infection such as hepatitis C virus. The compounds are phosphoramidate derivatives of nucleoside compounds derived from bases such as adenine and guanine. The glycoside moiety of the nucleoside compound can be substituted at the ss-2? position with methyl and the phosphoramidate group can be 1-naphthyl linked by —O— to the P atom. These compounds can be administered as pharmaceutical compositions, and methods for their preparation are also provided.

Abstract: The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and to methods to prevent the oncogenic activity of said fusion product.

Abstract: Molecules having a spacer unit, linker and recognition unit(s) are used for the treatment of various diseases, disorders and conditions. The compounds are useful in treating infectious diseases and diseases, disorders or conditions related thereto. Further, the methods for treating diseases, disorders or conditions involve recognition and binding of carbohydrate structures.

Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.

Abstract: By present invention it has been found that hypothermia decreases adhesion formation more specifically pneumoperitoneum-enhanced adhesion formation. A cooling system has been designed to reduce the peritoneal cavity temperature during surgery, while maintaining at all times a 100% relative humidity in order to prevent desiccation, and a regulatory unit designed to condition the insufflated gas to achieve this while minimalising the necessary cooling. This is a new method for more effectively preventing adhesion though cooling while preventing desiccation. In mice it was demonstrated that factors such as environmental temperature, anaesthesia, ventilation and pneumoperitoneum can be used to influence body temperature in order to prevent adhesion formation.

Abstract: The present invention provides a testing system allowing the simultaneous comparative evaluation of the behavior in a membrane process of two or more selected membranes (4). In a preferred embodiment said system allows the control of the hydrodynamics of the feeding liquid by means of stirrers (13).

Abstract: The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and to methods to prevent the oncogenic activity of said fusion product.

Abstract: Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis.

Abstract: In a first object the present invention provides a method for the inspection of the quality of the sealing of a packages and more specifically the method of the present invention allows the on-line inspection of the air-tightness of a package. Said method comprising the following steps of (i) acquiring the noise signal generated by the sealing equipment during the sealing of the package, (ii) analyzing the signal in order to determine the values of at least one physical parameter characterizing the noise signal and (iii) deciding on the quality of the sealing by comparing the determined value to a reference value for said physical parameter.

Abstract: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).

Abstract: The invention relates to the field of phagocytosis and more particularly to the field of neurons and neuron diseases. In particular the invention relates to the use of molecules capable of modulating the phagocytosis in neurons, more particularly to molecules modulating the activity of telencephalin.

Abstract: In a first object the present invention provides a method for the inspection of the quality of the sealing of a packages and more specifically the method of the present invention allows the on-line inspection of the air-tightness of a package. Said method comprising the following steps of (i) acquiring the noise signal generated by the sealing equipment during the sealing of the package, (ii) analyzing the signal in order to determine the values of at least one physical parameter characterizing the noise signal and (iii) deciding on the quality of the sealing by comparing the determined value to a reference value for said physical parameter.

Abstract: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).

Abstract: The present invention concerns a method for the separation and/or isolation of inhibitors of cellulolytic, xylanolytic and/or beta-glucanolytic enzymes, inhibitors obtainable by said method, and process for obtaining micro-organism, plant or plant material wherein the activity of the inhibitor according to the invention is increased or reduced and to the use of the inhibitor, using the cited micro-organism, plant or plant material and/or the use of endoxylanases selected or modified using these inhibitors in a variety of process and applications.

Abstract: This invention relates to a gene therapy method for inducing pulmonary vasodilation. More specifically, this invention involves introducing the nitric oxide synthase gene into lungs resulting in pulmonary vasodilation. This results in a hypotensive effect in the pulmonary circulation which does not significantly affect systemic blood pressure or cardiac index. This method is useful to treat primary pulmonary hypertension or pulmonary hypertension secondary to various disease states.

Abstract: The present invention is related to a method for post-oxidation heating of at least one substrate comprising at least a SiO2 layer or a SiO2/poly-Si layer structure, comprising the steps of: creating an inert gaseous ambient in a furnace, said ambient having a partial pressure within a predetermined range and said gaseous ambient comprising helium molecules, which have a suitable diameter for penetrating into the SiO2 and/or the poly-Si material; placing the substrate into said ambient; thereafter heating said furnace to a temperature of at least 200° C. for a predetermined period of time; cooling said furnace while maintaining said gaseous ambient in said predetermined pressure range in said furnace.

Abstract: The invention relates to methods for treating scar tissue, wherein the scar tissue is covered with a masking element, and the masking element is pressed onto the scar tissue with an adjustable force by means of a pressure control unit and which is connected with inflatable or suction members in the masking element. The invention also relates to a device for treating scar tissue, consisting of a masking element which contacts the scar tissue, a supporting part which presses the masking element onto the tissue and means for adjusting the force with which the masking element is pressed onto the tissue. In another embodiment, the device is provided such that an active substance can be delivered in a controlled manner to the scar tissue through the inflatable or suction members in the masking element.

Abstract: A new plasminogen activator which is very similar to the plasminogen activator from blood can be isolated in good amounts from the culture fluid of human melanoma cells.This new plasminogen activator has a strong thrombolytic effect and pharmaceutical compositions thereof may be used in the therapeutic treatment of thrombosis disorders.